Immunohistological staining of unknown chemokine RANTES/CCL5 expression in jawbone marrow defects-osteoimmunology and disruption of bone remodeling in clinical case studies targeting on predictive preventive personalized medicine.
Bead-based Luminex® analysis
Hyperactivated signaling pathways
Osteoimmunology
Osteonecrosis of the jawbone
Predictive preventive personalized medicine
Journal
The EPMA journal
ISSN: 1878-5077
Titre abrégé: EPMA J
Pays: Switzerland
ID NLM: 101517307
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
12
03
2019
accepted:
18
07
2019
entrez:
14
12
2019
pubmed:
14
12
2019
medline:
14
12
2019
Statut:
epublish
Résumé
Fatty degenerative osteonecrosis in the medullary spaces of the jawbone (FDOJ) may be identified as a lesser known source of RANTES/CCL5 (R/C) overexpression. The chemokine R/C also interferes with bone metabolism leading to osteolysis in areas affected by FDOJ. Many dental surgeries require functioning repair mechanisms and these may be disrupted by R/C overexpression. To clarify the way in which R/C expression from adipocytes in FDOJ causes a disturbance in osteogenesis and impacts on medullary stem cells by investigating the detection of R/C expression with immunochemical staining. We examined the tissue samples of 449 patients with FDOJ to assess the level of the chemokine R/C using bead-based Luminex® analysis. In six clinical case studies of FDOJ, we compared bone density, histological findings, R/C expression, and immunohistochemical staining. R/C is overexpressed by up to 30-fold in the 449 FDOJ cases when compared with healthy jawbone samples. The comparison of the six clinical cases consistently shows greatly reduced bone density, (i.e., osteolysis), but varies in terms of the level of agreement across the other three parameters. R/C from FDOJ sources may be implicated in several immune responses and considered a key pathogenetic pathway for increased adipogenesis rather than desirable osteogenesis. Adipocytes pathogenetically act via R/C expression in local FDOJ and systemically on the immune system. R/C may be regarded as an important trigger for possible pathological developments in the fate of hematopoietic stem cells. FDOJ is not a rigidly uniform process but reflects changing stages of development. The absence of correlating findings should not be interpreted as a misdiagnosis. It seems appropriate to direct further research in the field of "maxillo-mandibular osteoimmunology" focusing on R/C overexpression in FDOJ areas. This may contribute to the development of personalized strategies in preventive medicine.
Sections du résumé
BACKGROUND
BACKGROUND
Fatty degenerative osteonecrosis in the medullary spaces of the jawbone (FDOJ) may be identified as a lesser known source of RANTES/CCL5 (R/C) overexpression. The chemokine R/C also interferes with bone metabolism leading to osteolysis in areas affected by FDOJ. Many dental surgeries require functioning repair mechanisms and these may be disrupted by R/C overexpression.
OBJECTIVE
OBJECTIVE
To clarify the way in which R/C expression from adipocytes in FDOJ causes a disturbance in osteogenesis and impacts on medullary stem cells by investigating the detection of R/C expression with immunochemical staining.
MATERIALS AND METHODS
METHODS
We examined the tissue samples of 449 patients with FDOJ to assess the level of the chemokine R/C using bead-based Luminex® analysis. In six clinical case studies of FDOJ, we compared bone density, histological findings, R/C expression, and immunohistochemical staining.
RESULTS
RESULTS
R/C is overexpressed by up to 30-fold in the 449 FDOJ cases when compared with healthy jawbone samples. The comparison of the six clinical cases consistently shows greatly reduced bone density, (i.e., osteolysis), but varies in terms of the level of agreement across the other three parameters.
DISCUSSION
CONCLUSIONS
R/C from FDOJ sources may be implicated in several immune responses and considered a key pathogenetic pathway for increased adipogenesis rather than desirable osteogenesis. Adipocytes pathogenetically act via R/C expression in local FDOJ and systemically on the immune system.
CONCLUSION
CONCLUSIONS
R/C may be regarded as an important trigger for possible pathological developments in the fate of hematopoietic stem cells. FDOJ is not a rigidly uniform process but reflects changing stages of development. The absence of correlating findings should not be interpreted as a misdiagnosis. It seems appropriate to direct further research in the field of "maxillo-mandibular osteoimmunology" focusing on R/C overexpression in FDOJ areas. This may contribute to the development of personalized strategies in preventive medicine.
Identifiants
pubmed: 31832111
doi: 10.1007/s13167-019-00182-1
pii: 182
pmc: PMC6883018
doi:
Types de publication
Journal Article
Langues
eng
Pagination
351-364Informations de copyright
© The Author(s) 2019.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Science. 2006 Mar 31;311(5769):1880-5
pubmed: 16574858
Clin Cosmet Investig Dent. 2017 Nov 09;9:99-109
pubmed: 29184447
EPMA J. 2017 Mar 14;8(1):43-49
pubmed: 28620442
Int J Obes (Lond). 2009 Jan;33(1):54-66
pubmed: 19050672
Cell. 2008 Feb 22;132(4):681-96
pubmed: 18295583
Clin Oral Implants Res. 2001 Feb;12(1):79-84
pubmed: 11168274
Nat Med. 1996 Sep;2(9):1011-6
pubmed: 8782459
Dev Cell. 2002 Jul;3(1):137-47
pubmed: 12110174
EPMA J. 2016 Oct 25;7:23
pubmed: 27800037
J Formos Med Assoc. 2015 Feb;114(2):192-4
pubmed: 23856345
Nat Clin Pract Nephrol. 2007 Mar;3(3):164-70
pubmed: 17322928
Blood. 2012 Mar 15;119(11):2500-9
pubmed: 22289892
Int J Gen Med. 2013 Apr 22;6:277-90
pubmed: 23637551
EPMA J. 2018 Jun 8;9(3):331-343
pubmed: 30174768
J Oral Pathol. 1982 Dec;11(6):411-6
pubmed: 6819349
Oral Surg Oral Med Oral Pathol. 1992 Mar;73(3):307-19; discussion 319-20
pubmed: 1545963
EPMA J. 2015 May 06;6(1):10
pubmed: 25987906
Cranio. 2004 Oct;22(4):314-9
pubmed: 15532316
Oral Surg Oral Med Oral Pathol. 1974 Sep;38(3):404-13
pubmed: 4528570
Blood. 2001 Apr 1;97(7):1920-4
pubmed: 11264152
Breast Cancer (Auckl). 2014 May 21;8:89-96
pubmed: 24899812
J Oral Maxillofac Surg. 1986 Apr;44(4):268-73
pubmed: 3457122
Nat Rev Immunol. 2006 Oct;6(10):772-83
pubmed: 16998510
J Biol Regul Homeost Agents. 2017 Apr-Jun;31(2):321-327
pubmed: 28685531
Oncogene. 2002 May 13;21(21):3295-313
pubmed: 12032771
Cytokine. 1996 Jan;8(1):89-98
pubmed: 8742071
Mediators Inflamm. 2013;2013:480739
pubmed: 23997430
Nutrition. 2013 Jan;29(1):332-7
pubmed: 23237655
Clin Cosmet Investig Dent. 2014 Aug 21;6:71-9
pubmed: 25170282
Blood Cells Mol Dis. 2007 Nov-Dec;39(3):316-20
pubmed: 17629523